Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
Systemic lupus erythematosus (SLE) is an independent risk factor for atherosclerosis. Endothelial dysfunction is the earliest marker of atherosclerosis and is measured by flow mediated dilation (FMD) of the brachial artery. The purpose of the study was to measure FMD in mild, stable SLE patients and look for change in FMD with the immunosuppressant drug mycophenolate mofetil (MMF).
Epistemonikos ID: 87aadbca0828e66e6297004fcfbcb82e1f568ca9
First added on: May 05, 2024